Philip Streeter, PHD
- Email:
- click here
Lab Page: http://www.ohsu.edu/xd/research/research-cores/flow-cytometry/
Background
The long-term research goals of the Streeter laboratory are to contribute to the emerging fields of tissue engineering/repair and the development of tools for cancer diagnosis. Areas of research focus are beta cell replacement therapies for the treatment of diabetes, the identification of lung progenitor cell populations involved in lung repair, and in the diagnosis of pancreatic cancer.
Summary of Current Research
Dr. Streeter received his B.S. from the University of California-Davis in 1977. He attended graduate school at Kansas State University, receiving an M.S. in Laboratory Medicine in 1980 and a Ph.D. in Microbiology in 1985. Dr. Streeter continued his studies as a Postdoctoral Fellow in the Department of Pathology at Stanford University, investigating the molecular mechanisms involved in leukocyte recruitment to diverse lymphoid and extralymphoid tissues. In 1989 Dr. Streeter joined the biotechnology company SyStemix Inc., Palo Alto, CA, and moved to St. Louis, MO, in 1992 to work at Searle/Monsanto, now Pfizer. While working in these companies, Dr. Streeter led research efforts in the engineering of hematopoietic cytokines, the development of anti-tumor vaccines, and the identification of selective inhibitors of autoimmune disease. In 2000, Dr. Streeter joined Oregon Health & Science University and he is currently an Associate Professor in the Department of Medicine. In 2003 he became Director of the OHSU Hematopoietic Cell Processing Laboratory, and in 2004 he became a member of the Oregon Stem Cell Center, where he is Director of the Center's monoclonal antibody and flow cytometry core facilities and conducts independent research.
Selected Publications
"Epigenomic plasticity enables human pancreatic α to β cell reprogramming,"
"Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia.,"
"Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress,"
"The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma,"
"Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody,"
